Abou-Saleh Radwa H, Delaney Aileen, Ingram Nicola, Batchelor Damien V B, Johnson Benjamin R G, Charalambous Antonia, Bushby Richard J, Peyman Sally A, Coletta P Louise, Markham Alexander F, Evans Stephen D
Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, U.K.
Biophysics Group, Department of Physics, Faculty of Science, Mansoura University, Mansoura 35511, Egypt.
ACS Appl Bio Mater. 2020 Nov 16;3(11):7840-7848. doi: 10.1021/acsabm.0c00982. Epub 2020 Oct 30.
Microbubbles (MBs) are widely used as contrast enhancement agents for ultrasound imaging and have the potential to enhance therapeutic delivery to diseases such as cancer. Yet, they are only stable in solution for a few hours to days after production, which limits their potential application. Freeze-drying provides long-term storage, ease of transport, and consistency in structure and composition, thereby facilitating their use in clinical settings. Therapeutic microbubbles (thMBs) consisting of MBs with attached therapeutic payload potentially face even greater issues for production, stability, and well-defined drug delivery. The ability to freeze-dry thMBs represents an important step for their translation to the clinic. Here, we show that it is possible to freeze-dry and reconstitute thMBs that consist of lipid-coated MBs with an attached liposomal payload. The thMBs were produced microfluidically, and the liposomes contained either calcein, as a model drug, or gemcitabine. The results show that drug-loaded thMBs can be freeze-dried and stored for at least 6 months. Upon reconstitution, they maintain their structural integrity and drug loading. Furthermore, we show that their echogenicity is maintained post-freeze-drying. Depending on the gas used in the original bubbles, we also demonstrate that the approach provides a method to exchange the gas core to allow the formulation of thMBs with different gases for combination therapies or improved drug efficacy. Importantly, this work provides an important route for the facile off-site production of thMBs that can be reformulated at the point of care.
微泡(MBs)被广泛用作超声成像的造影剂,并且有潜力增强对癌症等疾病的治疗性给药。然而,它们在生产后仅在溶液中稳定存在数小时至数天,这限制了它们的潜在应用。冷冻干燥提供了长期储存、便于运输以及结构和成分的一致性,从而便于它们在临床环境中的使用。由附着有治疗载荷的微泡组成的治疗性微泡(thMBs)在生产、稳定性和明确的药物递送方面可能面临更大的问题。冷冻干燥thMBs的能力是其转化为临床应用的重要一步。在这里,我们表明可以冷冻干燥并重构由脂质包裹的微泡与附着的脂质体载荷组成的thMBs。thMBs通过微流控技术生产,脂质体包含作为模型药物的钙黄绿素或吉西他滨。结果表明,载药thMBs可以冷冻干燥并储存至少6个月。重构后,它们保持其结构完整性和药物负载。此外,我们表明它们在冷冻干燥后保持其回声性。根据原始气泡中使用的气体,我们还证明该方法提供了一种交换气体核心的方法,以允许配制用于联合治疗或提高药物疗效的含有不同气体的thMBs。重要的是,这项工作为在现场外轻松生产可在护理点重新配制的thMBs提供了一条重要途径。